Released on = November 14, 2006, 10:31 am

Press Release Author = Debra Thai

Industry = Biotech

Press Release Summary = Melanoma, a malignant tumor that arises in melanocytes, is
the most deadly of all skin cancers.

Press Release Body = Although it accounts for only 4% of all skin cancer cases,
melanoma is the leading cause of skin cancer deaths1. Several antigens expressed in
melanoma cells and recognized by T cells have been identified and used in developing
immunization approaches for tumor regression2. These include: MART-1/Melan-A, gp100,
Tyrosinase, p15, TRP-1 and beta-catenin2.

AnaSpec, a leading provider of integrated proteomics solutions, offers a broad
collection of peptide products for cancer research, including an extensive listing
of melanoma immunodominant epitopes and their analogs.

[Ala26]-Melan-A/MART-1 (26-35)
Melan-A/MART-1 (27-35)
Melan-A, MART 1 (26-35)
[Leu27]-Melan-A, MART 1 (26-35)
Melan-A/MART-1 (24-34)
MELAN-A/MART-1 (32-40)
Melanocyte Associated Antigen gp 100 (17-25)
Melanocyte Associated Antigen gp100
gp100 (476-485)
gp100 (570-579)
gp100 (457-466)
gp100 (614-622)
gp100 (639-647)
gp100 (619-627)
gp100 (178-187)
Tyrosinase (146-156)
Tyrosinase (206-214), T9206
[Asp370]-Tyrosinase (368-376)
Tyrosinase (1-9)
(Asn370) tyrosinase (368-376)
Tyrosinase (192-200)
Tyrosinase (56-70)
Tyrosinase (450-462)
Tyrosinase (243-251), core nonamer sequence
Tyrosinase (240-251)

For more information visit www.anaspec.com

References:
1. American Cancer Society: Cancer Facts and Figures-2006. Atlanta GA: American
Cancer Society, 2006.
2. Rosenberg, SA. J. National Cancer Inst. 88, 1635 (1996).


Web Site = http://www.anaspec.com

Contact Details = 2149 O\'Toole Ave.
San Jose, CA 95131
Tel: 800-452-5530
Fax: 408-452-5059
info@anaspec.com
www.anaspec.com